Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Trial Profile

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorolanib (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Acronyms DAVIO
  • Sponsors EyePoint Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2022 According to an EyePoint Pharmaceuticals media release, a late breaking abstract highlighting 12 month data from the Phase 1 DAVIO clinical trial evaluating EYP-1901 for the treatment of wet age related macular degeneration (wet AMD) has been selected for presentation at the American Society of Retinal Specialists (ASRS) 2022 Annual Meeting to be held in New York City from July 13 -16, 2022.
    • 10 Jun 2022 Results published in the EyePoint Pharmaceuticals Media Release
    • 12 Feb 2022 Interim Results published in the EyePoint Pharmaceuticals Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top